These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 18759643)
1. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. Haas M; Karcher K; Pandina GJ J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643 [TBL] [Abstract][Full Text] [Related]
2. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Findling RL; Aman MG; Eerdekens M; Derivan A; Lyons B; Am J Psychiatry; 2004 Apr; 161(4):677-84. PubMed ID: 15056514 [TBL] [Abstract][Full Text] [Related]
3. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. Aman MG; Binder C; Turgay A J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021 [TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Turgay A; Binder C; Snyder R; Fisman S Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284 [TBL] [Abstract][Full Text] [Related]
5. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. Reyes M; Croonenberghs J; Augustyns I; Eerdekens M J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):260-72. PubMed ID: 16768634 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Reyes M; Buitelaar J; Toren P; Augustyns I; Eerdekens M Am J Psychiatry; 2006 Mar; 163(3):402-10. PubMed ID: 16513860 [TBL] [Abstract][Full Text] [Related]
7. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. Croonenberghs J; Fegert JM; Findling RL; De Smedt G; Van Dongen S; J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):64-72. PubMed ID: 15608545 [TBL] [Abstract][Full Text] [Related]
8. Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder. Pandina GJ; Zhu Y; Cornblatt B J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):749-56. PubMed ID: 20035593 [TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Aman MG; De Smedt G; Derivan A; Lyons B; Findling RL; Am J Psychiatry; 2002 Aug; 159(8):1337-46. PubMed ID: 12153826 [TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQ. Aman M; Buitelaar J; Smedt GD; Wapenaar R; Binder C J Child Adolesc Psychopharmacol; 2005 Apr; 15(2):220-32. PubMed ID: 15910206 [TBL] [Abstract][Full Text] [Related]
11. Risperidone in the management of disruptive behavior disorders. Pandina GJ; Aman MG; Findling RL J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):379-92. PubMed ID: 16958564 [TBL] [Abstract][Full Text] [Related]
12. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353 [TBL] [Abstract][Full Text] [Related]
13. Risperidone and cognitive function in children with disruptive behavior disorders. Pandina GJ; Bilder R; Harvey PD; Keefe RS; Aman MG; Gharabawi G Biol Psychiatry; 2007 Aug; 62(3):226-34. PubMed ID: 17210137 [TBL] [Abstract][Full Text] [Related]
14. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586 [TBL] [Abstract][Full Text] [Related]
15. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. Snyder R; Turgay A; Aman M; Binder C; Fisman S; Carroll A; J Am Acad Child Adolesc Psychiatry; 2002 Sep; 41(9):1026-36. PubMed ID: 12218423 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Reyes M; Olah R; Csaba K; Augustyns I; Eerdekens M Eur Child Adolesc Psychiatry; 2006 Mar; 15(2):97-104. PubMed ID: 16523250 [TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Buitelaar JK; van der Gaag RJ; Cohen-Kettenis P; Melman CT J Clin Psychiatry; 2001 Apr; 62(4):239-48. PubMed ID: 11379837 [TBL] [Abstract][Full Text] [Related]
18. Risperidone oral solution versus standard tablets for the acute treatment of patients with schizophrenia. Kusumi I; Honda M; Ito K; Uemura K; Kumazawa Y; Ishikane T; Niide Y; Koyama T Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):537-40. PubMed ID: 21168464 [TBL] [Abstract][Full Text] [Related]
19. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. Hirschfeld RM; Eerdekens M; Kalali AH; Canuso CM; Khan AA; Karcher K; Palumbo JM Int Clin Psychopharmacol; 2006 Jan; 21(1):11-20. PubMed ID: 16317312 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of risperidone in children with disruptive behavioural disorders. Duhig MJ; Saha S; Scott JG J Paediatr Child Health; 2013 Jan; 49(1):19-26. PubMed ID: 22050179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]